Vimarsana
Biggest News Aggregation in the World

Resistance Collaborators News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Resistance Collaborators. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Resistance Collaborators Today - Breaking & Trending Today

The Nano Machines Made to Fight Antibiotic-Resistance and Cancer - Vimarsana News

The Nano Machines Made to Fight Antibiotic-Resistance and Cancer

Antibiotic-resistant bacteria were responsible for nearly 5 million deaths globally in 2019, as detailed in The Lancet. The rise and fall of antibiotics is a topic that is deeply personal to Dr. Ana Santos, who led the EU-funded project REBELLION.

A Spectroscopic Solution for Strain Typing and Discrimination - Vimarsana News

A Spectroscopic Solution for Strain Typing and Discrimination

Infrared (IR) spectroscopy demonstrates promise for rapid strain typing of yeast and bacteria, which could help improve proactive infection control strategies in health care settings.

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections - Vimarsana News

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

SCHLIEREN, Switzerland, October 09, 2023--LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorr

Source: yahoo.com
LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidru - Vimarsana News

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidru

SCHLIEREN, Switzerland--(BUSINESS WIRE)--LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platfor...

Ondine Biomedical presents research demonstrating high efficacy against Extensively Drug-Resistant (XDR) bacteria at ICPIC 2023 - Vimarsana News

Ondine Biomedical presents research demonstrating high efficacy against Extensively Drug-Resistant (XDR) bacteria at ICPIC 2023

Ondine Biomedical presents research demonstrating high efficacy against Extensively Drug-Resistant (XDR) bacteria at ICPIC 2023Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) has presented new research at the 2023 International Consortium on Prevention & Infection Control (ICPIC) in Geneva, demo...